Discussions with leaders: Johannes Czernin and Jérémie Calais talk with Michael Hofman, an Australian nuclear medicine physician and leader of international collaborative studies on prostate cancer, about innovation in clinical trial development. . . . . ***Page 1027***

Targeted radionuclide therapy trials: Mittra and Bodei review current trials in the National Institutes of Health database involving targeted radionuclide therapy, with an overview of the current landscape and future prospects.. . . . . ***Page 1031***

Pheochromocytoma and paraganglioma: Carrasquillo and colleagues provide an educational focus on these neuroendocrine tumors, emphasizing available imaging radiopharmaceuticals and the importance of genotype in selection of imaging agents. . . . . ***Page 1033***

Molecular imaging of liver transporters: Marie and colleagues describe characterization of hepatocyte transporters that have added to knowledge about ^{99m}Tc-mebrofenin kinetics and expanded the potential for translational and clinical applications assessing impaired liver function. . . . . ***Page 1043***

^{18}F-FDG for inflammation and infection: Wahl and colleagues laud the retirement of longstanding U.S. regulatory barriers to the use of ^{18}F-FDG PET for inflammation and infection indications and call for additional local evidence gathering to support wider reimbursement. . . . . ***Page 1048***

^{18}F-FDG PET in metastatic prostate cancer: Wibmer and colleagues assess the prognostic value of ^{18}F-FDG PET whole-body tumor burden parameters in patients with metastatic prostate cancer after first-line abiraterone or enzalutamide therapy. . . . . ***Page 1050***

PET/CT- vs. CT-guided lung biopsy: Cerci and colleagues compare ^{18}F-FDG PET/CT and CT performance in guiding percutaneous biopsies with histologic confirmation of suspect lung lesions.. . . . . ***Page 1057***

Combined PET/MRI and SLN N-staging: Weissinger and colleagues analyze the impact of ^{18}F-FDG PET/MR imaging in addition to sentinel lymph node biopsy on accuracy of lymph node staging in patients with cervical cancer. . . . . ***Page 1062***

Interim PET in DLBCL: Kurch and colleagues compare 3 competing methods of interim ^{18}F-FDG PET evaluation using data from a large clinical trial including patients with diffuse large B-cell lymphoma.. . . ***Page 1068***

^{99m}Tc-PSMA I&S dosimetry: Urbán and colleagues estimate the dosimetry of ^{99m}Tc–prostate-specific membrane antigen I&S using a hybrid method and depict tracer biodistribution and tumor-to-background ratios in patients with prostate cancer.. . . . . ***Page 1075***

^{68}Ga-PSMA-11 vs. ^{18}F-rhPSMA-7: Kroenke and colleagues compare the frequency of non–tumor-related uptake and tumor positivity with ^{68}Ga-PSMA-11 and ^{18}F-rhPSMA-7 PET/CT in patients with primary or recurrent prostate cancer...***Page 1082***

^{18}F-Fluciclovine and radiotherapy decisions: Abiodun-Ojo and colleagues report on changes in salvage radiation treatment management based on ^{18}F-fluciclovine PET/CT findings in patients with recurrent prostate cancer.. . . . . ***Page 1089***

^{131}I-GMIB-Anti-HER2-VHH1 in HER2 therapy: D'Huyvetter and colleagues detail initial results on the safety, biodistribution, radiation dosimetry, and tumor-imaging potential of this targeted radionuclide theranostic agent in healthy volunteers and patients with breast cancer.. . . . . ***Page 1097***

^{19}F/^{177}Lu-rhPSMA-7.3 endoradiotherapy: Yusufi and colleagues describe preclinical evaluation, including biodistribution, dosimetry, and therapeutic efficacy, of this radiohybrid prostate-specific membrane antigen ligand and compare it with ^{177}Lu-PSMA I&T.. . . . . ***Page 1106***

Low-dose ^{82}Rb PET MPI: Lassen and colleagues evaluate the feasibility of performing myocardial perfusion imaging using either a half- or quarter-dose ^{82}Rb protocol with reconstructions from acquired full-dose scans.***Page 1112***

Reducing ^{177}Lu time points: Devasia and colleagues compare a novel method for joint time–activity estimation, based on a statistical mixed model, complete data from prior patients, and 1 or 2 imaging points, with single-time-point SPECT/CT dosimetry approaches. . . . . ***Page 1118***

^{177}Lu-DOTA-ZOL safety and dosimetry: Fernández and colleagues document the safety and dosimetry of a single therapeutic dose of this new therapeutic radiopharmaceutical for bone metastasis using a series of SPECT/CT images and blood samples. . . . . ***Page 1126***

NRG–NCI Workshop on RPT Dosimetry: Roncali and organizers/attendees review optimal and developing approaches applied clinically to calculate absorbed dose in radiopharmaceutical therapy as discussed at a 2018 joint NRG Oncology and National Cancer Institute workshop. . . . . ***Page 1133***

^{18}F-Enzalutamide for androgen expression: Antunes and colleagues report on radiolabeling of this agent for PET assessment of androgen receptor density in prostate cancer and compare its in vitro and in vivo characteristics with those of ^{18}F-FDHT. . . . . ***Page 1140***

Fluorocarbon nanoemulsion for PET and MRI: Wang and colleague develop a functionalized nanoemulsion to serve as a platform for multimodal imaging probe exploration of molecular compositions enabling sensitive and precise imaging of inflammatory hotspots in vivo. . . . . ***Page 1146***

Modeling ^{18}F-Gln in breast cancer: Viswanath and colleagues detail model validation and performance assessment results for preclinical analysis and computer simulations of uptake kinetics of this PET agent that reflects glutamine transport and can be used to infer glutamine metabolism. . . . . ***Page 1154***

Mapping arginase expression with PET: Clemente and colleagues report on the synthesis and evaluation of 2 radiolabeled arginase inhibitors, ^{18}F-FMARS and 18F-FBMARS, with potential for PET staging of arginase-related pathophysiologies.. . . . . ***Page 1163***

SARS-CoV-2–related encephalitis: Tiraboschi and colleagues present notes on the contribution of ^{18}F-FDG PET/CT imaging in a challenging case of neurologic manifestations in a patient with severe acute respiratory syndrome coronavirus 2 infection. . . . ***Page 1171***